About this trial
Retrospective Analysis of Clinical Characteristics and Prognostic Factors in Hospitalized Pneumonia Patients from April 2023 to April 2026. Background: Pneumonia remains the leading cause of death from infectious diseases in adults worldwide, with an increasingly severe disease burden exacerbated by population aging and the frequent emergence of drug-resistant bacteria; in China, severe pneumonia accounts for a striking 13.58% to 20.05% of hospitalized cases. In recent years, shifts in the pathogen spectrum (e.g., COVID-19, influenza A) and patient demographic characteristics have posed new challenges for clinical management. However, existing studies mostly focus on single pathogens or specific populations (e.g., ICU patients), lacking systematic analyses of the full-disease course characteristics of general hospitalized pneumonia patients. Furthermore, in the post-pandemic era, the clinical phenotypes, treatment responses, and prognostic factors of pneumonia may have evolved, necessitating evidence-based support from real-world data. This study aims to conduct a retrospective analysis to clarify the epidemiological characteristics, etiological distribution, and prognostic factors influencing current hospitalized pneumonia patients, thereby providing a basis for optimizing diagnosis and treatment strategies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years old;
Meet the diagnostic criteria for pneumonia (acute onset + new infiltrates on imaging);
Have a positive result from pathogen testing;
Time from onset to admission ≤ 72 hours (to ensure being in the acute phase of the disease);
Disqualifiers
1) Patients with severely lacking medical records;
Trial population
From April 2023 to April 2026, all adult patients who were hospitalized due to pneumonia and met the diagnostic criteria
Trial design
Cohort
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
28-day all-cause mortality rate
Secondary outcomes
Demographic characteristics
Demographic data (age, sex, etc.)
Comorbidities
Comorbidities, such as chronic obstructive pulmonary disease (COPD), diabetes mellitus, and cardiovascular diseases.
Symptomatic manifestations
Symptomatic manifestations (e.g., fever, cough, dyspnea)
Laboratory tests
Laboratory tests (including blood routine, liver and kidney function, etc.)
Other outcomes
Utilization of Antimicrobial Agents
Clinical Outcomes (cured, improved, deceased)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Zhonghao Fang
Lead sponsor
Guangzhou Medical University
Sponsor institution
Fifth Affiliated Hospital of Guangzhou Medical University
Collaborator
This trial is not recruiting at the moment. You can still explore other options: